Dr. Elliott Antman is Professor of Medicine and Associate Dean for Clinical/Translational Research at Harvard Medical School, a Senior Investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, a Senior Physician in the Cardiovascular Division of the Brigham and Women's Hospital in Boston, Massachusetts, and President of the American Heart Association (2014-2015).
As a Senior Investigator in the TIMI Study Group, he has published on the use of serum cardiac markers for diagnosis and prognosis of patients with unstable angina and acute myocardial infarction, cyclooxygenase and cardiovascular risk, and antithrombotic therapy for acute coronary syndromes. His ongoing research studies help refine diagnostic and therapeutic modalities in routine clinical use today including cardiac specific troponins and novel antithrombotic agents.
At Brigham and Women's Hospital, Dr. Antman has been recognized for his active role and interest in education and training. He is the recipient of many awards from the housestaff, regularly participates in Professor's Rounds, and has been honored for his contributions by the Harvard Medical School when it awarded him the A. Clifford Barger Excellence in Mentoring Award in 2001.
In 2009, Dr. Antman became Director of the Harvard Catalyst Program for Education in Clinical and Translational Science. The goal of this program is to establish the infrastructure for coordination, integration, and oversight of clinical/translational postgraduate educational and training opportunities throughout the entire Harvard University system.
Dr. Antman participates actively in American Heart Association (AHA) and American College of Cardiology (ACC) activities, locally, nationally, and internationally. He was the Chairman of the joint ACC/AHA Task Force on Practice Guidelines from January 2003 through December 2005. He continues his work with the Task Force as a member of several Writing Committees (STEMI [Writing Committee Chair], UA/NSTEMI]. From 2011-12, Dr. Antman chaired the AHA's Committee on Scientific Sessions Programs and introduced the AHA's Emerging Science Webinar Series. Dr. Antman is on the AHA's National Board of Directors, chairs the AHA Science and Advisory Coordinating Committee and is a member of the AHA Advocacy Coordinating Committee. He is the recipient of the Meritorious Achievement Award from the AHA (2006) and is the recipient of the James B. Herrick Award for Outstanding Achievement in Clinical Cardiology (Council on Clinical Cardiology)in 2010.
Dr. Antman is married to Dr. Karen Antman, who is the Dean of Boston University School of Medicine and Provost of the Boston University Medical Center.
Christopher P. Cannon, MD has served a senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, leading trials such as TACTICS-TIMI 18, PROVE IT-TIMI 22, and CLARITY-TIMI 28. He currently is the principal investigator for the IMPROVE IT, SOLID-TIMI 52 and North American PI for the REVEAL- HPS3-TIMI 55 trial.
He earned his MD from Columbia University College of Physicians and Surgeons in New York, and after completing his residency in internal medicine at Columbia Presbyterian Medical Center, he was a cardiovascular fellow at Brigham and Women's Hospital.
Dr. Cannon has published over 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 17 books. He has served as editor-in-chief of the Science and Quality section of American College of Cardiology's website, www.Cardiosource.org. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association.
Dr. Robert P. Giugliano, MD is a Senior Investigator with the TIMI Study Group, Staff Physician in the Cardiovascular Division at Brigham and Women's Hospital, and Associate Professor of Medicine at Harvard Medical School.
He graduated Summa Cum Laude, Phi Beta Kappa (Mathematics) from Dartmouth College (1985), receiving a medical degree at Harvard Medical School (1989). Dr. Giugliano completed residency and chief residency at Cedars-Sinai Medical Center (UCLA affiiliate,1989-93) and cardiology fellowship at Massachusetts General Hospital (1993-6).
In 1996, Dr. Giugliano joined the Brigham and Women's Hospital as a Medicine Research Fellow in the Thrombolysis in Myocardial Infarction (TIMI) Study Group directed by Eugene Braunwald, and completed a Science Masters (Epidemiology) at the Harvard School of Public Health. In 1997, he joined the Cardiovascular Division faculty of the Brigham and Women's Hospital and has served as the principal investigator for 9 multicenter clinical trials at TIMI.
His areas of research interests include novel antithrombotic, fibrinolytic agents, and lipid-lowering therapies, and patient outcomes following Acute Coronary Syndromes (ACS). He has authored more than 200 articles and chapters, and delivered hundreds of lectures. Dr. Giugliano is the Principal Investigator for the ENGAGE-AF TIMI 48 trial of the factor Xa inhibitor edoxaban in patients with fibrillation. He is also a member of the Operations Committees and Lead TIMI Investigator for the IMPROVE-IT trial evaluating ezetimibe in 18,000 patients post ACS; the FOURIER trial studying evolocumab, a PCSK9 inhibitor, in hyperlipidemic patients with prior cardiovascular disease; and the , EARLY ACS trial of eptifibatide in ACS.
Dr. Giugliano serves on numerous Data Safety Monitoring Boards, clinical endpoint committees, and Holter/ECG Core Laboratories. He actively participates in the clinical activities of the Cardiovascular Division, attending in the Levine Cardiac Intensive Care Unit, telemetry unit, and consult services, and sees patients in a busy growing outpatient practice.
David A. Morrow, MD, MPH is the Director of the Samuel A. Levine Cardiac Unit in the Division of Cardiovascular Medicine at Brigham and Women's Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Morrow earned his medical degree from Harvard Medical School and a Masters in Public Health with a concentration in clinical study design and interpretation from the Harvard School of Public Health. He completed his medical residency in Internal Medicine and fellowship in Cardiovascular Medicine at Brigham and Women's Hospital.
Dr. Morrow is a Senior Investigator in the Thrombolysis in Myocardial Infarction Study Group at Brigham and Women's Hospital with a research focus in the management of unstable and stable coronary artery disease, and he directs the TIMI Biomarker Program.
He is an internationally recognized expert in risk stratification in patients with ischemic heart disease. He has served on the National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines Committee on Biochemical Cardiac Markers for which he led the clinical section on acute coronary syndromes, and on the Program Committee for the American Heart Association Council on Clinical Cardiology. He is a member of the Global Task Force for a Universal Definition of Myocardial Infarction and of the American College of Cardiology/American Heart Association Guidelines Committee for Management of ST-elevation Myocardial Infarction. He sits on the editorial boards of the American Heart Journal, Circulation, Clinical Chemistry, European Heart Journal: Acute Cardiovascular Care, and the Journal of the American College of Cardiology. He is a special section Co-Editor for Continuing Medical Education at Circulation. Dr. Morrow has more than 150 original scientific reports, reviews, editorials, book chapters and electronic publications in his areas of expertise, and is the editor of Cardiovascular Biomarkers, a text on application of biomarkers in Cardiovascular disease.
Deepak L. Bhatt MD, MPH is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women's Hospital and a Senior Investigator in the TIMI Study Group.
After graduating as valedictorian from the Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University. He completed a Masters in Public Health at Harvard University. His internship and residency in internal medicine were performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention as well as serving as Chief Interventional Fellow at Cleveland Clinic where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship and as Associate Director of the Cardiovascular Medicine Fellowship. He also served as Associate Director of the Cleveland Clinic Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System where he served for several years.
Dr. Bhatt has authored or co-authored over 600 publications. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as chair of COGENT and helped lead STAMPEDE. He serves as co-chair of the REACH registry. He is also co-PI of SAVOR-TIMI 53 and SYMPLICITY HTN-3. He is the current Chair of the AHA-GWTG Steering Committee. He is Associate Editor for clinical trials for the ACC's Cardiosource. He is the Editor-in-Chief of the Harvard Heart Letter.
Stephen D. Wiviott, MD, FACC is a graduate of University of Pennsylvania (Mathematics, Magna Cum Laude) in 1990 and Harvard Medical School (Honors) in 1996. He served as a Medical House Officer and Chief Medical Resident at Brigham and Women's Hospital. Following his medical residency training, he served as a Cardiology Fellow at Johns Hopkins Hospital and as a Cardiovascular Research Fellow with the TIMI Study Group with the Cardiovascular Division of Brigham and Women's Hospital. After completion of his training he has joined the faculty of the Cardiovascular Division of Brigham and Women's Hospital and serves as Associate Professor of Medicine at Harvard Medical School, as well as a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group. He attends in the Lown Cardiovascular Intensive Care Unit at BWH.
As a Senior Investigator with the TIMI Study Group, Dr. Wiviott has played important roles in the planning, implementation, and interpretation of several multicenter, national, and international clinical trials in ACS and studying antiplatelet therapies. He has played leadership roles in the JUMBO-TIMI 26 trial and the TRITON-TIMI 38 trial, the major phase II and III trials of prasugrel. He was the Principal Investigator (PI) of PRINCIPLE-TIMI 44, a study comparing high-dose clopidogrel with prasugrel in patients undergoing PCI, and of the TIMI 38 Coronary Stent Registry. He has also served key roles in trials of secondary prevention of Cardiovascular Disease as an executive committee member of REVEAL, and co-PI of DECLARE – TIMI 58 and CAMELLIA – TIMI 61. He is the Chairman of the TIMI Clinical Events Committee, and an expert in clinical event definitions and adjudications.
Dr. Wiviott is an author of more than 100 peer-reviewed publications in major medical and cardiovascular journals and of multiple chapters in major cardiovascular textbooks, including Braunwald's Heart Disease and Cardiovascular Therapeutics, a companion to Braunwald's Heart Disease. He has delivered local, national, and international lectures in the field of acute coronary syndromes, platelet biology, established and novel antiplatelet agents, and anticoagulants, and prevention. Areas of clinical and research interest include acute coronary syndromes, platelet biology, platelet inhibitors, and cholesterol-lowering therapy, and secondary prevention of CAD.
Jessica L. Mega, MD, MPH is Associate Professor at Harvard Medical School and Associate Physician in Cardiovascular Medicine at Brigham and Women's Hospital. She is a Senior Investigator with the TIMI Study Group.
Dr. Mega graduated with honors and distinction from Stanford University and was inducted into Phi Beta Kappa. She received her medical degree from Yale University School of Medicine, where she was the recipient of the Parker Prize and Alpha Omega Alpha membership. She obtained her Masters of Public Health with a focus on biostatistics and epidemiology at the Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women's Hospital and Cardiology Fellowship at Massachusetts General Hospital. She has received multiple awards including the Laennec Society Award and Samuel A. Levine Award from the AHA and the Zipes Distinguished Young Scientist Award from the ACC. She is a fellow of the AHA and ACC.
As a clinical trialist, Dr. Mega has been involved in the leadership of several studies, including ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51, testing the use of novel anticoagulants in ACS patients. Additionally, she has developed ways to use genetics and biomarkers to better evaluate and treat patients with cardiovascular disease. Specifically, Dr. Mega and colleagues demonstrated that variants in the CYP2C19 gene influence the response to the antiplatelet medication clopidogrel. She was then the principal investigator and FDA IND sponsor for the ELEVATE-TIMI 56 trial, studying escalating doses of clopidogrel based on CYP2C19 genotype. The TIMI Study Group's Genetics Program continues to expand, and the genetic causes of cardiovascular/metabolic diseases, as well as the response to a wide array of therapies, are being explored. Dr. Mega's research has been published in journals such as the New England Journal of Medicine, Lancet, JAMA, Circulation, and JACC, and supported by research grants from the AHA and NIH. On leave of absence.
Benjamin Scirica, MD, MPH graduated from Harvard Medical School and trained in internal medicine and cardiovascular medicine at Brigham and Women's Hospital in Boston, Massachusetts. He has a Master of Public Health degree from Harvard School of Public Health. He is currently Senior Investigator at the TIMI Study Group , an attending cardiologist and Director of Quality Initiatives in the cardiovascular division at Brigham and Women's Hospital, and an associate professor of medicine at Harvard Medical School.
His research interests center on the identification and application of novel cardiac biomarkers and electrocardiographic techniques. He is the Director of the TIMI ECG Core Laboratory, which has analyzed over 20,000 continuous and static ECGs from multiple trials in acute coronary syndromes, including the ExTRACT-TIMI 25, CLARITY-TIMI 28, DISPERSE-2, PLATO, and MERLIN-TIMI 36 trials. He was principal investigator of the AVANT GARDE-TIMI 43 trial and co-investigator of the MERLIN-TIMI 36, TRA 2Pº-TIMI 50, and SAVOR-TIMI 53 trials. He is currently co-Principal Investigator of CAMELLIA-TIMI 61.
Dr. Scirica has authored or co-authored over 100 peer-reviewed articles, serves on the editorial board of ACCEL and Elsevier's PracticeUpdate.com, and is a reviewer for multiple journals, including The Lancet, Circulation, and Journal of the American College of Cardiology (JACC). He practices cardiology in the cardiac intensive care unit, cardiology in-patient service, and the Watkins Cardiovascular Clinic at Brigham and Women's Hospital.